US Patent
US8821920 — Therapeutic patch for transdermal delivery of capsaicin
Formulation · Assigned to LTS Lohmann Therapie Systeme AG · Expires 2030-03-26 · 4y remaining
Vulnerability score
48/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects a therapeutic patch for transdermal delivery of capsaicin or a compound analogous to capsaicin.
USPTO Abstract
The invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent, in which the therapeutic compound is present in completely dissolved form and the concentration of the therapeutic compound in the microreservoir droplets is below the saturation concentration. The invention furthermore relates to a process for its production and its use in the treatment of neuropathic pain.
Drugs covered by this patent
- Qutenza (CAPSAICIN) · Averitas
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.